Cutaneous Lupus Erythematosus – Pipeline Insight, 2024

Cutaneous Lupus Erythematosus – Pipeline Insight, 2024

DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cutaneous Lupus Erythematosus Understanding

Cutaneous Lupus Erythematosus: Overview

Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:

• LE-specific cutaneous LE has been classified as acute, subacute, intermittent and chronic. Lesions may be localised or generalised. In LE-specific cutaneous LE, lesions are often induced by exposure to sunlight.
• LE-nonspecific cutaneous LE may relate to systemic LE or another autoimmune disease.

A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test). Treatment may vary depending upon type of Cutaneous Lupus Erythematosus: The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous Lupus Erythematosus.

Cutaneous Lupus Erythematosus Emerging Drugs Chapters

This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous Lupus Erythematosus Emerging Drugs

• BIIB059: Biogen

Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Currently it is being evaluated in Phase II clinical trial in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy.

• SAR443122: Sanofi

SAR443122 is a peripherally-restricted small molecule inhibitor of RIPK1 being evaluated in patients with cutaneous lupus erythematosus (CLE). Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors. This includes peripherally restricted molecules such as SAR443122 (DNL758) and CNS-penetrant molecules such as DNL788 (SAR443820). A Phase II clinical study is assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus.

Further product details are provided in the report……..

Cutaneous Lupus Erythematosus: Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cutaneous Lupus Erythematosus

There are approx. 10+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus. The companies which have their Cutaneous Lupus Erythematosus drug candidates in the most advanced stage, i.e. phase II include Biogen.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous Lupus Erythematosus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.

Cutaneous Lupus Erythematosus Report Insights

• Cutaneous Lupus Erythematosus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cutaneous Lupus Erythematosus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cutaneous Lupus Erythematosus drugs?
• How many Cutaneous Lupus Erythematosus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous Lupus Erythematosus?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous Lupus Erythematosus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cutaneous Lupus Erythematosus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hoth Therapeutics
• Zylo Therapeutics
• Sanofi
• Gilead Sciences
• Bristol-Myers Squibb
• Merck KGaA
• Kyowa Kirin Co., Ltd.
• Priothera Ltd.
• Centessa Pharmaceuticals
• Horizon Therapeutics

Key Products

• GSK2646264
• BIIB 059
• AEA-loaded Z-pods
• SAR443122
• Lanraplenib
• BMS-986256
• Enpatoran
• Deucravacitinib
• KK4277
• Mocravimod
• VIB7734